Engineered ligand and receptor based fusion proteins as next generation cancer therapeutics
July 16-20, 2017
We use natural ligands and receptors as scaffolds for protein engineering to leverage their inherent biophysical and biochemical properties. I will present our recent data on therapeutic candidates engineered to possess high affinity and unique target specificities for applications in oncology.
Jennifer R. Cochran, "Engineered ligand and receptor based fusion proteins as next generation cancer therapeutics" in "Biochemical and Molecular Engineering XX", Wilfred Chen, University of Delaware, USA Nicole Borth, Universität für Bodenkultur, Vienna, Austria Stefanos Grammatikos, UCB Pharma, Belgium Eds, ECI Symposium Series, (2017). http://dc.engconfintl.org/biochem_xx/137